Drug intelligence / Profile preview

Burotam

Development stage
Phase 4
Lead developer
Yung Shin Pharmaceutical Industry
Modality
Small Molecules
Administration
Intravenous Injection, Intravenous Infusion
01

Overview

Burotam is an injectable antibiotic combination comprising cefoperazone sodium, a third-generation cephalosporin antibiotic, and sulbactam sodium, a beta-lactamase inhibitor. Cefoperazone exerts its bactericidal effect by interfering with bacterial cell wall synthesis through binding to penicillin-binding proteins. Sulbactam irreversibly inhibits a wide range of bacterial beta-lactamase enzymes, thereby protecting cefoperazone from degradation and extending its spectrum of activity against resistant bacteria. This combination is indicated for the treatment of various bacterial infections, including those of the respiratory and urinary tracts, intra-abdominal infections, pelvic inflammatory disease, and skin and soft tissue infections.

Brand names
BurotamBrosym
Other names
布洛坦乾粉注射劑Burotam Powder for InjectionBurotam Inj.(複)(CPZ/SUL)Burotam(Brosym)2g/vial
02

Targets

β-lactamasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Burotam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burotam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call